Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: The aim of this cohort study was to investigate the risk of malignant neoplasms and mortality in patients with diabetes treated either with human insulin or with one of three insulin analogues. METHODS: Data were provided by the largest German statutory health insurance fund (time-frame: January 1998 to June 2005 inclusive), on patients without known malignant disease who had received first-time therapy for diabetes mellitus exclusively with human insulin, aspart, lispro or glargine. The primary outcome was the diagnosis of a malignant neoplasm. Data were analysed by multiple Cox regression models adjusting for potential confounders. RESULTS: A total of 127,031 patients were included, with a mean follow-up time of 1.63 (median 1.41, maximum 4.41) years. A positive association between cancer incidence and insulin dose was found for all insulin types. Because patients receiving combined therapy with insulin analogues and human insulin were excluded, the mean daily dose was much lower for glargine than for human insulin, and a slightly lower cancer incidence in the glargine group was found. After adjusting for dose, a dose-dependent increase in cancer risk was found for treatment with glargine compared with human insulin (p < 0.0001): the adjusted HR was 1.09 (95% CI 1.00 to 1.19) for a daily dose of 10 IU, 1.19 (95% CI 1.10 to 1.30) for a daily dose of 30 IU, and 1.31 (95% CI 1.20 to 1.42) for a daily dose of 50 IU. No increased risk was found for aspart (p = 0.30) or lispro (p = 0.96) compared with human insulin. CONCLUSIONS/INTERPRETATION: Considering the overall relationship between insulin dose and cancer, and the lower dose with glargine, the cancer incidence with glargine was higher than expected compared with human insulin. Our results based on observational data support safety concerns surrounding the mitogenic properties of glargine in diabetic patients. Prospective long-term studies are needed to further evaluate the safety of insulin analogues, especially glargine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1799]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Miller, R. G. (1981) · Cited by 3,336
Applied Survival Analysis: Regression Modeling of Time-to-Event Data
Hosmer, D. W., Lemeshow, S. A., & May, S. J. (2008) · Cited by 3,030
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,004 · cited 1×
“As this study was intended to generate hypotheses, we made no adjustments for multiple testing [23].”
MethodSelf-citationMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“In particular, we analysed a potential influence of metformin therapy, for which potential effects on cancer incidence have been previously discussed [24].”
BackgroundSurvival Analysis: A Self-Learning Text
Carpenter, M. (1997) · Technometrics · doi:10.1080/00401706.1997.10485091 · Cited by 1,811 · cited 1×
“We checked the proportional hazard assumption graphically by plotting log(-log survival time) versus log survival time and by a formal test based on Schoenfeld residuals [ 22 ].”
MethodApplied Survival Analysis: Regression Modeling of Time‐to‐Event Data
Hosmer, D. W., Lemeshow, S., & May, S. (2008) · Wiley Series in Probability and Statistics · doi:10.1002/9780470258019 · Cited by 1,298
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105 · cited 1×
“53) has been calculated for endometrial cancer [6, 7].”
BackgroundDiabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038 · cited 1×
“An OR of 1.82 (95% CI 1.66 to 1.89) has been reported for pancreatic cancer, and an RR of 2.10 (95% CI 1.75 to 2.53) has been calculated for endometrial cancer [6, 7 ]. Similar results have been reported for other cancer entities.”
ResultInfluentialDiabetes mellitus and risk of breast cancer: A meta‐analysis
Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22717 · Cited by 875 · cited 1×
“28) for breast cancer [3–5].”
Survival Analysis: A Self-Learning Text
Carpenter, M., & Kleinbaum, D. G. (1997) · Technometrics · doi:10.2307/1270914 · Cited by 812 · cited 1×
“We checked the proportional hazard assumption graphically by plotting log(-log survival time) versus log survival time and by a formal test based on Schoenfeld residuals [22].”
MethodKurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 2×
“Comparison of the mitogenic potency of insulin analogues relative to human insulin in cell experiments showed that B10Asp was tenfold and glargine (A21Gly,B31Arg,B32Arg human insulin) was eightfold more potent, whereas lispro (B28Lys,B29Pro human insulin) and aspart (B28Asp human insulin) were slightly less potent [10…”
BackgroundSurvival Analysis: A Self-Learning Text
Kleinbaum, D. G., & Klein, M. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29150-4 · Cited by 676
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
Friberg, E., Orsini, N., Mantzoros, C. S., & Wolk, A. (2007) · Diabetologia · doi:10.1007/s00125-007-0681-5 · Cited by 562 · cited 1×
“53) has been calculated for endometrial cancer [6, 7].”
BackgroundSandhu, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.972 · Cited by 496 · cited 1×
“Although insulin has predominantly metabolic effects, it also has weak direct and indirect mitogenic properties [1, 2].”
BackgroundOwens, D. R., Zinman, B., & Bolli, G. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05842-1 · Cited by 373 · cited 1×
“Because of safety concerns, long-term studies to evaluate the safety of insulin analogues have been demanded [ 15 ].”
BackgroundHorvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366 · cited 1×
“We think that, especially in type 2 diabetes mellitus, the potential harm of glargine must be weighed against rather minor potential therapeutic advantages [18, 26, 27].”
BackgroundInsulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350 · cited 1×
“, who found indications that the duration of insulin treatment was positively associated with an increase in the incidence of colorectal cancer among type 2 diabetic patients [8].”
BackgroundDiabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304 · cited 1×
“28) for breast cancer [3–5].”
Insulin promotion of colon tumors in rats.
Tran, T. T., Medline, A., & Bruce, W. R. (1996) · PubMed · Cited by 275
Survival Analysis: A Self-Learning Text (2nd ed.)
Cavanaugh, J. E. (2006) · Quarterly Publications of the American Statistical Association · Cited by 266
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 243 · cited 1×
“We think that, especially in type 2 diabetes mellitus, the potential harm of glargine must be weighed against rather minor potential therapeutic advantages [18, 26, 27].”
BackgroundGoldberg, J. D., & Le, C. T. (1999) · Technometrics · doi:10.1080/00401706.1999.10485684 · Cited by 219 · cited 2×
“The scale of the continuous covariates was assessed using a graphical procedure proposed by Hosmer and Lemeshow [20].”
MethodWeinstein, D., Simon, M., Yehezkel, E., Laron, Z., & Werner, H. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.912 · Cited by 179 · cited 1×
“In addition, recent experiments with colorectal, prostate and breast cancer cell lines showed that glargine and lispro stimulated cancer cell proliferation significantly more than human insulin did [12].”
BackgroundGoldberg, J. D., & Le, C. T. (1999) · Technometrics · doi:10.2307/1270580 · Cited by 175
The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake
Drejer, K. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080305 · Cited by 151 · cited 1×
“In vivo carcinogenicity was first demonstrated for the B10Asp insulin analogue, which, in contrast to human insulin, induced mammary tumours in rats [13].”
BackgroundBornfeldt, K., Gidl�f, R. A., Wasteson, Å., Lake, M., Skottner, A., & Arnqvist, H. J. (1991) · Diabetologia · doi:10.1007/bf00405001 · Cited by 113 · cited 1×
“Although it has been shown that the differences in growth-promoting and mitogenic potencies between human insulin and insulin analogues, as well as between the analogues themselves, are related to different affinities to the IGF-I receptor, the exact mechanisms are not fully understood, and the clinical importance of…”
BackgroundEvaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice
Stammberger, I., Bube, A., Durchfeld-Meyer, B., Donaubauer, H., & Troschau, G. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096306 · Cited by 90 · cited 1×
“Animal experiments using high-dose glargine have been inconclusive because of the excessive short-term mortality from repeated severe hypoglycaemia and subsequent neuronal necrosis or cardiovascular failure [14].”
BackgroundProliferative effects of insulin analogues on mammary epithelial cells
Mayer, D., Shukla, A., & Enzmann, H. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801900645 · Cited by 79 · cited 1×
“The proliferative effects of insulin analogues on mammary epithelial cells relative to human insulin have recently been analysed; at physiologically relevant concentrations, a significantly higher proliferative effect on MCF-7 breast cancer cells was found for glargine, but not for aspart or lispro [11].”
BackgroundReliability of causes of death in persons with Type I diabetes
hlhauser, I. M. X. F., Sawicki, P. T., Blank, M., Overmann, H., Richter, B., & Berger, M. (2002) · Diabetologia · doi:10.1007/s00125-002-0957-8 · Cited by 55 · cited 1×
“In our opinion, this issue should be investigated using a prospective study design, and a reliable assessment of causes of death should be performed by a clinical review committee [25].”
Self-citation
Cited by
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
“Recently, a series of widely publicized epidemiologic analyses examined a possible association between insulin use and/or use of the long-acting insulin analog glargine (91,110,113,114) and an increase in risk of cancer.”
Shared Risk Factors in Cardiovascular Disease and Cancer
Koene, R. J., Prizment, A. E., Blaes, A., & Konety, S. H. (2016) · Circulation · doi:10.1161/circulationaha.115.020406 · Cited by 1,494
“In contrast, a potential increased risk is associated with insulin analogues.(87,88) The general patterns demonstrated across several studies support the hyperinsulinemia hypothesis, where therapies that increase circulating insulin levels increase cancer risk, and those that lower insulin resistance and circulating i…”
ResultDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033
Metadata
- Authors
- Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T.
- Affiliations
- Institute for Quality and Efficiency in Health Care (DE)
- University of Cologne (DE)
- Wissenschaftliches Institut der AOK (DE)
- Corresponding author
- Hemkens, L. G.
- Venue
- Diabetologia
- Published
- 2009-06-30
- Volume
- 52
- Issue
- 9
- Pages
- 1732-1744
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC2723679
- OpenAlex
- W2108747912
- Cited by
- 607
- References
- 28
- Citations by year
- 2026: 11 · 2025: 4 · 2024: 13 · 2023: 8 · 2022: 9 · 2021: 9 · 2020: 22 · 2019: 18 · 2018: 27 · 2017: 26 · 2016: 21 · 2015: 41 · 2014: 50 · 2013: 66 · 2012: 64
- FWCI
- 37.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Diabetologia (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Keywords
- diabetes mellitus, insulin analogues, human insulin, glargine, insulin aspart, insulin lispro, cancer risk, cancer, insulin dose, mortality, drug safety
- MeSH terms
- Insulin Glargine, Aged, Aged, 80 and over, Analysis of Variance, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Germany, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Neoplasms, Regression Analysis, Reproducibility of Results, Cohort Studies, Proportional Hazards Models, Patient Selection, Diabetes Complications, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

